# Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

> **NCT00492063** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 2654 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Cell culture-derived trivalent subunit influenza vaccine (cTIV)
- **BIOLOGICAL:** Egg-derived trivalent subunit influenza vaccine (TIV)

## Key facts

- **NCT ID:** NCT00492063
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2004-12
- **Final completion:** 2005-05
- **Target enrollment:** 2654 (ACTUAL)
- **Last updated:** 2016-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492063, "Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00492063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*